{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:24:44Z","timestamp":1777793084139,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.yapd.2022.03.009","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:14:52Z","timestamp":1655759692000},"page":"133-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Hemophilia A Management"],"prefix":"10.1016","volume":"69","author":[{"given":"Sukjoo","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Felipe","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10040","key":"10.1016\/j.yapd.2022.03.009_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ajh.2830160312","article-title":"Factor VIII: structure and function in blood clotting","volume":"16","author":"Chavin","year":"1984","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6905a1","article-title":"Evaluation of CDC's hemophilia surveillance program - universal data collection (1998-2011) and community counts (2011-2019), United States","volume":"69","author":"Schieve","year":"2020","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","article-title":"Occurrence of hemophilia in the United States. the hemophilia surveillance system project investigators","volume":"59","author":"Soucie","year":"1998","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-09-3879","article-title":"Bleeding in carriers of hemophilia","volume":"108","author":"Plug","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000503889","article-title":"Hemophilia A in females: considerations for clinical management","volume":"143","author":"Bryant","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.yapd.2022.03.009_bib7","author":"National Hemophilia Foundation"},{"issue":"11","key":"10.1016\/j.yapd.2022.03.009_bib8","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.yapd.2022.03.009_bib9","first-page":"827","article-title":"Bleeding disorders: characterization, dental considerations and management","volume":"72","author":"Israels","year":"2006","journal-title":"J\u00a0Can Dent Assoc"},{"issue":"Suppl 6","key":"10.1016\/j.yapd.2022.03.009_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.yapd.2022.03.009_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.yapd.2022.03.009_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2141.2005.05952.x","article-title":"Optimal haemophilia care versus the reality","volume":"132","author":"Bolton-Maggs","year":"2006","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib13","first-page":"691","article-title":"Modern treatment of haemophilia","volume":"73","author":"Berntorp","year":"1995","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/hae.13425","article-title":"Principles of haemophilia care: the Asia-Pacific perspective","volume":"24","author":"Dunkley","year":"2018","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.yapd.2022.03.009_bib15","first-page":"437","article-title":"Mortality among males with hemophilia: relations with source of medical care. the hemophilia surveillance system project investigators","volume":"96","author":"Soucie","year":"2000","journal-title":"Blood"},{"issue":"9_suppl","key":"10.1016\/j.yapd.2022.03.009_bib16","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1177\/1076029618807583","article-title":"A\u00a0practical guide to the management of the fetus and newborn with hemophilia","volume":"24","author":"Moorehead","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/hae.13748","article-title":"Standard and water rehabilitation: An analysis of over 14 years' experience in patients with haemophilia or other clotting factor disorders after orthopaedic surgery","volume":"25","author":"Passeri","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib19","first-page":"50","article-title":"The effect of aquatic exercise therapy on muscle strength and joint's range of motion in hemophilia patients","volume":"4","author":"Kargarfard","year":"2013","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.yapd.2022.03.009_bib20","series-title":"Oral care for people with hemophilia or a hereditary bleeding tendency","author":"Scully","year":"2008"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2516.2011.02716.x","article-title":"Access to primary dental care for patients with inherited bleeding disorders","volume":"18","author":"Kalsi","year":"2012","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.yapd.2022.03.009_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.bdj.2013.1097","article-title":"Guidance on the dental management of patients with haemophilia and congenital bleeding disorders","volume":"215","author":"Anderson","year":"2013","journal-title":"Br Dent J"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2516.2007.01453.x","article-title":"Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs","volume":"13","author":"Eyster","year":"2007","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2516.2006.01311.x","article-title":"Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia","volume":"12","author":"Rattray","year":"2006","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib25","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood-2004-09-3501","article-title":"Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy","volume":"107","author":"Tsoukas","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/hae.13549","article-title":"Recommendations on multidisciplinary management of elective surgery in people with haemophilia","volume":"24","author":"Escobar","year":"2018","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.yapd.2022.03.009_bib27","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.14543","article-title":"Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A","volume":"176","author":"Batty","year":"2017","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.yapd.2022.03.009_bib29","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.yapd.2022.03.009_bib31","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia a: results of the joint outcome continuation study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.yapd.2022.03.009_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","article-title":"New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development","volume":"16","author":"Kurnik","year":"2010","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.yapd.2022.03.009_bib33","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.yapd.2022.03.009_bib34","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia a: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.yapd.2022.03.009_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000488060","article-title":"Extended half-life factor VIII and factor IX preparations","volume":"45","author":"Graf","year":"2018","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/hae.12887","article-title":"Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc","volume":"22","author":"Berntorp","year":"2016","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.yapd.2022.03.009_bib38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib39","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D'Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.yapd.2022.03.009_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.yapd.2022.03.009_bib42","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0029-1245107","article-title":"Improvements in factor VIII inhibitor detection: from bethesda to nijmegen","volume":"35","author":"Verbruggen","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2516.2011.02671.x","article-title":"Recommendations for assessment, monitoring and follow-up of patients with haemophilia","volume":"18","author":"de Moerloose","year":"2012","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.15942","article-title":"How I treat children with haemophilia and inhibitors","volume":"186","author":"Young","year":"2019","journal-title":"Br J Haematol"},{"issue":"Suppl 3","key":"10.1016\/j.yapd.2022.03.009_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.yapd.2022.03.009_bib48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.yapd.2022.03.009_bib49","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.yapd.2022.03.009_bib50","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.yapd.2022.03.009_bib52","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.yapd.2022.03.009_bib53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.yapd.2022.03.009_bib55","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.yapd.2022.03.009_bib56","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib57","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1111\/hae.13871","article-title":"ST-segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII","volume":"26","author":"Gundabolu","year":"2020","journal-title":"Haemophilia"},{"issue":"17","key":"10.1016\/j.yapd.2022.03.009_bib58","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2017008409","article-title":"Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis","volume":"1","author":"Seaman","year":"2017","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.yapd.2022.03.009_bib59","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/bloodadvances.2018015859","article-title":"Emicizumab should be prescribed independent of immune tolerance induction","volume":"2","author":"Le Quellec","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yapd.2022.03.009_bib62","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.yapd.2022.03.009_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"10.1016\/j.yapd.2022.03.009_bib64","first-page":"017","article-title":"Adenoviral vectors for hemophilia gene therapy","volume":"2","author":"Brunetti-Pierri","year":"2013","journal-title":"J\u00a0Genet Syndr Gene Ther"},{"issue":"5","key":"10.1016\/j.yapd.2022.03.009_bib65","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.yapd.2022.03.009_bib66","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.yapd.2022.03.009_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.yapd.2022.03.009_bib68","article-title":"Phase I\/II trial of SPK-8011: stable and durable FVIII expression after AAV gene transfer for hemophilia A [abstract]","volume":"5","author":"George","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.yapd.2022.03.009_bib69","author":"von Drygalski"},{"issue":"3","key":"10.1016\/j.yapd.2022.03.009_bib70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.yapd.2022.03.009_bib71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"5837","key":"10.1016\/j.yapd.2022.03.009_bib72","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1126\/science.1142658","article-title":"AAV vector integration sites in mouse hepatocellular carcinoma","volume":"317","author":"Donsante","year":"2007","journal-title":"Science"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310122000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310122000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:12:23Z","timestamp":1758744743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310122000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0065310122000093"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2022.03.009","relation":{},"ISSN":["0065-3101"],"issn-type":[{"value":"0065-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Hemophilia A Management","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2022.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}